Trials / Completed
CompletedNCT03667547
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
An Open-label Single Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-0518 1200 mg (600 mg Tablet × 2) in Healthy Japanese Male Participants
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate safety, tolerability, and pharmacokinetics of a single 1200-mg dose of raltegravir (MK-0518, ISENTRESS®) in healthy Japanese male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raltegravir | Raltegravir 600 mg tablet |
Timeline
- Start date
- 2018-09-27
- Primary completion
- 2018-10-23
- Completion
- 2018-10-23
- First posted
- 2018-09-12
- Last updated
- 2019-10-02
- Results posted
- 2019-10-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03667547. Inclusion in this directory is not an endorsement.